This study will be looking at the survival rate of patients treated with an investigational medicine called Vorinostat in combination with standard radiation treatment and the standard chemotherapeutic agent Temozolomide. Participants will undergo a routine history and physical exam, tumor evaluations with magnetic resonance imaging (MRI), and routine blood tests. You may qualify for the study is you: 

• Are a male or non-pregnant female age 18 or older 
• Have had surgical biopsy or surgical removal of the tumor. (Note: you must start study treatment greater than 2 weeks after, but less than 5 weeks after biopsy or surgery) 
• Are willing to practice effective method of birth control during study participation. You may not qualify for this study if you have/had: 
• Other active cancers requiring therapy to control disease 
• Prior chemotherapy or radiation therapy for any brain tumor 
• Had any prior anti-tumor treatment (other than corticosteroids) including any investigational agents OR you are: 
• Receiving any other investigational agents 
• Pregnant or nursing You will receive no money for participating in this trial. Study medication is provided by Merck and Co.